New stocks won the week: The Renaissance IPO Index rebounded +8.6%.
After three straight down weeks, the IPO market crushed the S&P 500, which rose +3.6%. Our IPO Index is back above +20% for the year, now that July’s AI sell-off has reversed.
Biotech IPOs continued their winning streak, with four new listings from clinical-stage drug developers. Braveheart Bio (Nasdaq: BRVE), which targets cardiovascular disease, completed the week's largest IPO and popped +65.6%, boasting strong Phase 2 data and a cornerstone investment from Fidelity. The week's other biotech deals (ATTO, LTGO, BLSM) were more modest, but none finished negative.
SpaceX had the most talked-about IPO lock-up release of all time, after its first public earnings announcement. The stock finished the week up +23%, nearly back to the offer price. Improved AI sentiment helped, but as Avery and Matt mentioned on the previous W&L podcast, lower-than-expected insider selling after a lock-up release can be a buy signal.
The Big Picture: Biotech and AI infrastructure will continue to be major themes in the fall. And if SpaceX continues this rally, that raises the odds of a mega-IPO from Anthropic or OpenAI.
For now, it’s “last call” for the 2026 summer IPO market. A typical IPO calendar would give companies one more week to launch their offerings before the annual August lull.
The Week Ahead: China-based Londian Wason New Energy Tech (NYSE: FOIL) is raising $75 million in a deal led by Cantor. The company produces copper foils used in batteries. We don't count closed-end funds in our IPO stats, but Robinhood Ventures Fund II (NYSE: RVII) aims to raise $200 million, with a portfolio of dozens of smaller private tech companies.
Index Movers: The IPO Index’s winner and loser this week were both AI-powered diagnostics companies. Downtrodden Caris Life Sciences (CAI) jumped +45.1% on a beat-and-raise quarter. BillionToOne (BLLN) slid -32.6% after the much-hyped company put up a decent quarter but merely reiterated 2026 guidance.
Take care,
Bill Smith
CEO and Founder
Renaissance Capital
|
Biggest price changes through
Aug 7th
in the
Renaissance IPO Index
|
||
|---|---|---|
| Top 5 | ||
| Caris Life Sciences | CAI | 45.1% |
| X-Energy | XE | 38.9% |
| Firefly Aerospace | FLY | 31.4% |
| Chime Financial | CHYM | 26.6% |
| CoreWeave | CRWV | 26.3% |
| Bottom 5 | ||
| BillionToOne | BLLN | -32.6% |
| UL Solutions | ULS | -14.7% |
| Medline | MDLN | -10.3% |
| Klaviyo | KVYO | -6.8% |
| Figma | FIG | -4.2% |
| Sectors | ||
| Utilities | 14.7% | |
| Industrials | 11.5% | |
| Technology | 10.0% | |
| Financials | 9.8% | |
| Health Care | 4.5% | |
| Consumer Discretionary | 1.5% | |
| Real Estate | 1.0% | |
| Energy | -0.5% | |
| Consumer Staples | -2.5% | |
Renaissance IPO ETF (NYSE symbol: IPO) tracks the Renaissance IPO Index
The Renaissance IPO Index returned 8.6% last week vs. 3.6% for the S&P 500.
